FEATURED NEWS
NEWS: USE OF HSC TARGETED LNP TO GENERATE A MOUSE MODEL OF LETHAL α-THALASSEMIA AND TREATMENT VIA LENTIVIRAL GENE THERAPY (JUL 2024)
Congratulations to Ying Tam and Barb Mui, co-authors of a recent study featured in Blood. They collaborated with scientists from the University of Pennsylvania to develop a mouse model of the hematological disease a-thalassemia in which deletion of the α-globin genes induces a lethal phenotype associated with high levels of red blood cells in circulation. Click to read more info.
NEWS: CHRISTOPHER SWEENEY NAMED EXECUTIVE DIRECTOR, INTELLECTUAL PROPERTY AT ACUITAS THERAPEUTICS (USA), INC. (JUL 2024)
Acuitas Therapeutics, Inc.’s Chief Legal Officer & Vice President of Business Development, Miranda Lam, KC, recently announced that Christopher Sweeney had joined Acuitas Therapeutics (USA), Inc. as Executive Director of Intellectual Property. Click to read more info.
NEWS: TRANSIENT GROWTH FACTOR EXPRESSION VIA mRNA IN LIPID NANOPARTICLES PROMOTES HEPATOCYTE CELL THERAPY IN MICE (JUN 2024)
Congratulations to Ying Tam, co-author of a recent study featured in Nature Communications. He collaborated with scientists from the Gouon-Evans Lab at the Center for Regenerative Medicine and the Weissman and Pardi Labs at University of Pennsylvania Perelman School of Medicine studying the stimulation of key regenerative pathways in transplanted PHHs using human HGF and human EGF delivered with mRNA-LNP drastically improves donor PHH engraftment as an alternative to liver transplantation and restores liver function. Click to read more info.